Biotech’s AI Race Is No Longer About Models. It’s About Infrastructure.
Roche’s latest Nvidia build is not just another AI headline.
Abu Dhabi Wants to Own Longevity Biotech—and Juvenescence Is the Test Case
Abu Dhabi’s push to become a global life-sciences hub has
Chai Discovery’s $130m bet: can “CAD for molecules” make biologics faster and cheaper?
With a $130m Series B, the startup is betting that
When the FDA Starts Trusting Algorithms: What AIM-NASH Means for Liver Drug Trials
Regulators have just qualified an AI system to score liver
The AI science factory arrives: why Lila’s $1.3bn valuation matters beyond biotech
Lila’s Nvidia-backed raise is about more than money. It is
AstraZeneca’s $555m Algen bet: why the pharma giant is buying AI-generated targets, not equity
AstraZeneca has inked a deal worth “up to” $555 million
How AI is Revolutionizing Antibiotic Discovery to Combat Drug-Resistant Bacteria
Antibiotic resistance poses a significant global health threat, rendering many
Michigan-Based Biotech Startup CircNova Secures $3.3M Seed Funding to Advance AI-Driven Circular RNA Therapies
CircNova, a Michigan-based biotechnology startup, has successfully raised $3.3 million
Unlocking New Frontiers: How Generative AI is Transforming Protein Design and Drug Discovery
Abstract This report explores the transformative impact of generative artificial
AI-Powered Drug Repurposing by BioXcel Therapeutics Accelerates Development of New Neuropsychiatric Treatments
1. Introduction BioXcel Therapeutics is a biopharmaceutical company leveraging artificial
MOST POPULAR
